{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:37:01Z","timestamp":1781242621393,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abemaciclib plus fulvestrant was approved in Europe following publication of the MONARCH-2 trial and recommended to enter the NICE Cancer Drugs Fund for HR+\/HER2\u2212 advanced breast cancer. We aimed to assess MONARCH-2 generalisability to England clinical practice using real-world NHS trust data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified patients receiving abemaciclib plus fulvestrant from April to December 2019 in the NHS England Blueteq and Systemic Anti-Cancer Therapy data, with follow-up to March 2024. We calculated overall survival (OS) from treatment initiation until death, and treatment-free survival (TFS) and chemotherapy-free survival (CFS) from initiation until post-discontinuation treatment or death (restricting CFS to chemotherapy). We measured outcomes using Kaplan\u2013Meier methodology and compared to MONARCH-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median OS was 25.9 months [95% CI: 23.7, 28.4] (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009876), compared to 46.7 months (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009446) in MONARCH-2. Differences in gender, age and performance status did not explain OS differences. Median TFS was 11.6 months [95% CI: 10.3, 12.5] compared to a median PFS of 16.9 months in MONARCH-2. Median CFS was 15.3 months [95% CI: 13.8, 16.7], compared to 25.5 months in MONARCH-2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>MONARCH-2 trial data are not generalisable to this real-world cohort, which had notably shorter OS, TFS and CFS that could not be explained by differences in measured patient characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03396-z","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:27:09Z","timestamp":1774895229000},"page":"1440-1446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer\u2014comparing real-world outcomes in England to the MONARCH-2 trial"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8531-3314","authenticated-orcid":false,"given":"Jack","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0246-4026","authenticated-orcid":false,"given":"Sarah","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5865-1370","authenticated-orcid":false,"given":"Katherine","family":"Thackray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4912-8502","authenticated-orcid":false,"given":"Emma","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"3396_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3396_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","volume":"123","author":"M Nadji","year":"2005","unstructured":"Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered. Am J Clin Pathol. 2005;123:21\u20137.","journal-title":"Am J Clin Pathol"},{"key":"3396_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.21037\/tcr.2019.11.46","volume":"9","author":"ZH Xu","year":"2020","unstructured":"Xu ZH, Zhang H, Wei DH, Xie LL, Xu CS. Cyclin-dependent kinase 4\/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis. Transl Cancer Res. 2020;9:657\u201368.","journal-title":"Transl Cancer Res"},{"key":"3396_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/DDDT.S137783","volume":"12","author":"SP Corona","year":"2018","unstructured":"Corona SP, Generali D. Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2\u2013; advanced breast cancer. Drug Des Devel Ther. 2018;12:321\u201330.","journal-title":"Drug Des Devel Ther"},{"key":"3396_CR5","unstructured":"Study Details. A study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive HER2 negative breast cancer. ClinicalTrials.gov [Internet]. [cited 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02107703."},{"key":"3396_CR6","unstructured":"NHS England. Cancer Drugs Fund [Internet]. [cited 2025 May 30]. Available from: https:\/\/www.england.nhs.uk\/cancer\/cdf\/."},{"key":"3396_CR7","unstructured":"Overview. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Guidance. NICE [Internet]. [cited 2025 May 30]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta725."},{"key":"3396_CR8","unstructured":"3 Committee discussion. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Guidance. NICE [Internet]. [cited 2025 May 30]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta725\/chapter\/3-Committee-discussion."},{"key":"3396_CR9","unstructured":"Systemic Anti-Cancer Therapy (SACT) data set\u2014NDRS [Internet]. [cited 2025 May 30]. Available from: https:\/\/digital.nhs.uk\/ndrs\/data\/data-sets\/sact."},{"key":"3396_CR10","unstructured":"Commissioner High Cost Drugs\u2014Blueteq Ltd [Internet]. [cited 2025 30]. Available from: https:\/\/blueteq.com\/commissioner-high-cost-drugs-new\/."},{"key":"3396_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus Fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2. JAMA Oncol. 2020;6:116.","journal-title":"JAMA Oncol"},{"key":"3396_CR12","unstructured":"Personal Demographics Service\u2014NHS England Digital [Internet]. [cited 2025 May 30]. Available from: https:\/\/digital.nhs.uk\/services\/personal-demographics-service."},{"key":"3396_CR13","doi-asserted-by":"crossref","unstructured":"Rocque GB, Gilbert A, Williams CP, Kenzik KM, Nakhmani A, Kandhare PG, et al. Prior treatment time affects survival outcomes in metastatic breast cancer. JCO Clin Cancer Inform. 2020;4:500\u201313.","DOI":"10.1200\/CCI.20.00008"},{"key":"3396_CR14","doi-asserted-by":"crossref","unstructured":"Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66:337\u201350.","DOI":"10.3322\/caac.21342"},{"key":"3396_CR15","doi-asserted-by":"crossref","unstructured":"Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care. 2020;15:347\u201354.","DOI":"10.1159\/000508675"},{"key":"3396_CR16","doi-asserted-by":"crossref","unstructured":"Miller WR. Identification and mechanisms of endocrine resistance. Breast Cancer Res. 2008;10:S19.","DOI":"10.1186\/bcr2179"},{"key":"3396_CR17","doi-asserted-by":"crossref","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"3396_CR18","doi-asserted-by":"crossref","unstructured":"Lambertini M, Blondeaux E, Bisagni G, Mura S, De Placido S, De Laurentiis M, et al. Prognostic and clinical impact of the endocrine resistance\/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies. EClinicalMedicine. 2023;59:101931.","DOI":"10.1016\/j.eclinm.2023.101931"},{"key":"3396_CR19","doi-asserted-by":"crossref","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395.","DOI":"10.1016\/j.annonc.2021.09.019"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03396-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:29:12Z","timestamp":1777530552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03396-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,20]]}},"alternative-id":["3396"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03396-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data and methods presented in this study were collected and performed under the National Disease Registries Directions 2021, in accordance with sections 254(1) and 254(6) of the 2012 Health and Social Care Act. Further ethical approval and informed consent were not required as per the definition of research according to the UK Policy Framework for Health and Social Care Research. This work uses data that have been provided by patients, collected and submitted by the NHS as part of their care and support. The data are collated, maintained and quality assured by the National Disease Registration Service, which is part of NHS England.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}